Pulmonx Reports 6% Q3 Revenue Growth, Narrows Loss And Maintains 2026 Revenue Outlook
Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, with net loss narrowing to $8.4M. Gross margin improved to 76%. The company maintained its 2026 revenue outlook of $90M-$92M and expects full-year gross margin of 77%. U.S. and international revenues both increased, with international growth affected by China's distributor restart.
How this was made
The 30-second read
Why it matters
The quarter shows a return to year-over-year revenue growth and meaningful expense reduction, while management maintained the 2026 revenue range and provided gross margin and operating expense expectations.
Market read
Traders can reassess near-term risk/reward based on fresh quarterly performance and whether the China restart and cost realignment continue to translate into sustained revenue growth and further loss narrowing.
What to watch
China restart timing and the renewed commercial activity after registration certificate renewal could create volatility in subsequent quarters; also, operating expense guidance includes non-cash stock-based compensation, which may affect how investors judge underlying cash profitability.
Background
Pulmonx is a medical device company reporting Q3 2026 results, including revenue growth, margin improvement, and cost realignment efforts.
Ticker impact
Pulmonx reported Q3 2026 revenue of $22.8M (+6% YoY), narrowed net loss, and maintained 2026 revenue outlook of $90M-$92M.
Likely upward bias as investors price in stabilization of revenue growth and narrowing losses, with follow-through dependent on whether China restart and expense discipline sustain.
The article provides fresh quarterly datapoints (revenue growth, margin, expense decline, loss narrowing) plus reiterated full-year revenue and margin/expense expectations, which typically supports near-term sentiment even without guidance raise.
Market effects
Adds incremental signal of demand and cost discipline for respiratory medical device peers, but no direct sector-wide catalyst is disclosed.
China distributor absence is cited as a driver of international growth variability, highlighting regional execution risk for medtech revenue.
Primarily company-specific; no broader macro or regulatory shift is mentioned.
Counterpoint
Unchanged full-year revenue guidance suggests the market may already expect stabilization, so the stock reaction could fade if investors focus on cash burn and the $22M expected full-year cash decrease.
Key entities
- companyPulmonx Corporation
Reported Q3 2026 revenue growth, narrowed losses, and reiterated full-year 2026 revenue outlook.
- executiveGlen French
CEO who attributed plans to commercial execution, clinical initiatives, and realigned cost structure.

